Pipeline
CTIM-76: Claudin 6 x CD3
CTIM-76 is a bispecific antibody that incorporates a highly selective CLDN6 binding arm and a CD3 binding scFv domain in an IgG format with a silenced Fc that is designed to be functionally monovalent to avoid aberrant T-cell activation and to enhance the safety profile. Research has demonstrated that CTIM-76 is potent with specific lysis of CLDN6+ cancer cells over normal cells and can activate cytotoxic T cells without concomitant activation of free cytokines – critical determinants of immunotherapy safety and activity.
CT-95: Mesothelin x CD3
CT-95 is a bispecific antibody featuring two moderate-affinity mesothelin binding arms and two CD3 single-chain Fv domains in a monovalent IgG format with a silenced Fc, designed to enhance safety by preventing aberrant T-cell activation. Its membrane-proximal and cooperative binding to mesothelin ensures high selectivity and stable engagement with tumor cells, while minimizing off-target effects from shed mesothelin. CT-95 delivers potent, tumor-specific lysis and cytotoxic T cell activation without triggering excessive free cytokines, supporting a highly targeted and safer immunotherapeutic approach.
CT-202: Nectin-4 x CD3
CT-202 is a bispecific antibody engineered in an IgG format, featuring two Nectin-4 binding arms and two CD3-binding single-chain Fv domains, along with a silenced Fc region designed to be functionally monovalent. This structure helps prevent unwanted T-cell activation and improves safety. While Nectin-4 is present in healthy skin, sweat glands, and hair follicles, making targeted therapies prone to dermatological side effects, CT-202 employs pH-dependent binding to both Nectin-4 and CD3, minimizing interaction with healthy tissues and optimizing selectivity for tumor cells within the tumor microenvironment.